PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
RANI vs. HOWL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between RANI and HOWL is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

RANI vs. HOWL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
-43.64%
-37.29%
RANI
HOWL

Key characteristics

Sharpe Ratio

RANI:

-0.43

HOWL:

-0.80

Sortino Ratio

RANI:

-0.09

HOWL:

-1.71

Omega Ratio

RANI:

0.99

HOWL:

0.81

Calmar Ratio

RANI:

-0.51

HOWL:

-0.86

Martin Ratio

RANI:

-0.83

HOWL:

-1.25

Ulcer Index

RANI:

59.40%

HOWL:

63.78%

Daily Std Dev

RANI:

115.06%

HOWL:

99.65%

Max Drawdown

RANI:

-96.43%

HOWL:

-93.45%

Current Drawdown

RANI:

-95.06%

HOWL:

-93.21%

Fundamentals

Market Cap

RANI:

$101.29M

HOWL:

$62.39M

EPS

RANI:

-$1.05

HOWL:

-$1.52

Total Revenue (TTM)

RANI:

$0.00

HOWL:

$1.89M

Gross Profit (TTM)

RANI:

-$503.00K

HOWL:

$967.00K

EBITDA (TTM)

RANI:

-$36.19M

HOWL:

-$47.05M

Returns By Period

In the year-to-date period, RANI achieves a 26.28% return, which is significantly higher than HOWL's -6.76% return.


RANI

YTD

26.28%

1M

22.70%

6M

-43.65%

1Y

-47.09%

5Y*

N/A

10Y*

N/A

HOWL

YTD

-6.76%

1M

1.47%

6M

-37.27%

1Y

-79.15%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

RANI vs. HOWL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RANI
The Risk-Adjusted Performance Rank of RANI is 2626
Overall Rank
The Sharpe Ratio Rank of RANI is 2424
Sharpe Ratio Rank
The Sortino Ratio Rank of RANI is 3030
Sortino Ratio Rank
The Omega Ratio Rank of RANI is 3030
Omega Ratio Rank
The Calmar Ratio Rank of RANI is 1616
Calmar Ratio Rank
The Martin Ratio Rank of RANI is 2828
Martin Ratio Rank

HOWL
The Risk-Adjusted Performance Rank of HOWL is 77
Overall Rank
The Sharpe Ratio Rank of HOWL is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of HOWL is 33
Sortino Ratio Rank
The Omega Ratio Rank of HOWL is 66
Omega Ratio Rank
The Calmar Ratio Rank of HOWL is 33
Calmar Ratio Rank
The Martin Ratio Rank of HOWL is 1313
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

RANI vs. HOWL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Rani Therapeutics Holdings, Inc. (RANI) and Werewolf Therapeutics, Inc. (HOWL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for RANI, currently valued at -0.43, compared to the broader market-2.000.002.00-0.43-0.80
The chart of Sortino ratio for RANI, currently valued at -0.09, compared to the broader market-4.00-2.000.002.004.006.00-0.09-1.71
The chart of Omega ratio for RANI, currently valued at 0.99, compared to the broader market0.501.001.502.000.990.81
The chart of Calmar ratio for RANI, currently valued at -0.51, compared to the broader market0.002.004.006.00-0.51-0.86
The chart of Martin ratio for RANI, currently valued at -0.83, compared to the broader market-10.000.0010.0020.0030.00-0.83-1.25
RANI
HOWL

The current RANI Sharpe Ratio is -0.43, which is higher than the HOWL Sharpe Ratio of -0.80. The chart below compares the historical Sharpe Ratios of RANI and HOWL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.50SeptemberOctoberNovemberDecember2025February
-0.43
-0.80
RANI
HOWL

Dividends

RANI vs. HOWL - Dividend Comparison

Neither RANI nor HOWL has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

RANI vs. HOWL - Drawdown Comparison

The maximum RANI drawdown since its inception was -96.43%, roughly equal to the maximum HOWL drawdown of -93.45%. Use the drawdown chart below to compare losses from any high point for RANI and HOWL. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%SeptemberOctoberNovemberDecember2025February
-95.06%
-92.67%
RANI
HOWL

Volatility

RANI vs. HOWL - Volatility Comparison

Rani Therapeutics Holdings, Inc. (RANI) has a higher volatility of 29.06% compared to Werewolf Therapeutics, Inc. (HOWL) at 17.47%. This indicates that RANI's price experiences larger fluctuations and is considered to be riskier than HOWL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%70.00%SeptemberOctoberNovemberDecember2025February
29.06%
17.47%
RANI
HOWL

Financials

RANI vs. HOWL - Financials Comparison

This section allows you to compare key financial metrics between Rani Therapeutics Holdings, Inc. and Werewolf Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab